Concerns are being raised about a possible increased chance of heart attack and heart-related deaths in patients taking rosiglitazone, an ingredient in three drugs used to treat type 2 diabetes: Avandia, Avandaryl, and Avandamet.

There is agreement by several organizations [...] that the [Avandia] risk deserves serious attention and follow-up.

They are:

• American Association of Clinical Endocrinologists
• American College of Cardiology
• American Diabetes Association
• American Heart Association
• Endocrine Society